SQ-3370 is under clinical development by Shasqi and currently in Phase II for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SQ-3370’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SQ-3370 is under development for the treatment of solid tumors, pediatric sarcomas, advanced soft tissue sarcoma, relapsed or recurrent squamous-cell head and neck cancer. The drug candidate comprise of two components SQL-70, a hyaluronic acid-based biomaterial and SQP-33, a prodrug of doxorubicin. SQP-33 is administered through intravenous route and SQL-70 is administered through intratumoral route. It acts by targeting DNA topoisomerase II and DNA. It is developed based on Shasqi’s local activation technology. It was under development for platinum refractory ovarian cancer recurrent and/or metastatic uterine carcinoma, fallopian tube cancer, peritoneal cancer or uterine sarcoma.
Shasqi is a clinical stage biotechnology company which works to enable patients to beat cancer without poisoning their bodies. The company’s CAPAC Platform is modular and can be applied to a broad range of drugs that are otherwise limited by toxicity. Shasqi is headquartered in San Francisco, California, the US.
For a complete picture of SQ-3370’s drug-specific PTSR and LoA scores, buy the report here.